- Personalis Inc. (PSNL, Financial) expands its strategy by enhancing its collaboration with Tempus AI.
- Analysts predict significant movements with target prices ranging between $5.00 and $9.00.
- GuruFocus estimates a potential downside of 73.04% based on GF Value metrics.
Personalis Inc. (PSNL) has strategically expanded its partnership with Tempus AI, now encompassing colorectal cancer within their exclusive commercialization agreement. This move is set to enhance the utilization of their innovative NeXT Personal test, designed to monitor cancer recurrence and immunotherapy responses. The collaboration is slated to continue through November 2029, marking a significant extension in their cooperative efforts.
Wall Street Analysts Forecast
Wall Street analysts have issued their one-year price targets for Personalis Inc. (PSNL, Financial), with projections ranging from a high estimate of $9.00 to a low of $5.00, averaging out to $7.25. This average target suggests a potential upside of 5.07% from the current stock price of $6.90. Investors seeking additional details can refer to the Personalis Inc. (PSNL) Forecast page.
The consensus recommendation from eight brokerage firms places Personalis Inc. at an average rating of 1.9, which is classified as "Outperform." This rating is part of a scale where 1 reflects a Strong Buy and 5 indicates a Sell.
GuruFocus GF Value Analysis
According to GuruFocus estimates, the GF Value for Personalis Inc. (PSNL, Financial) in one year is anticipated to be $1.86. This estimation points to a considerable downside of 73.04% from the current price of $6.90. The GF Value is GuruFocus' measurement of a stock's fair trading value, determined by evaluating historical trading multiples alongside predictions of the company's business growth and performance. For a deeper dive into these estimates and insights, please visit the Personalis Inc. (PSNL) Summary page.
